UBS Maintains Neutral on Accendra Health, Raises Price Target to $4.5
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
UBS analyst Kevin Caliendo maintains Accendra Health (NYSE:ACH) with a Neutral and raises the price target from $3 to $4.5.
UBS analyst Kevin Caliendo maintains Accendra Health (NYSE:ACH) with a Neutral and raises the price target from $3 to $4.5.